Switching to Cefepime for Persistent Fever in Pyelonephritis
Yes, switching to cefepime is appropriate for this patient who remains febrile on ceftriaxone, and the recommended dose is 2 g IV every 12 hours. 1
Rationale for Switching
Your patient's persistent fever on ceftriaxone raises concern for possible ESBL-producing E. coli, which is increasingly common and renders ceftriaxone ineffective. Studies demonstrate that empirical ceftriaxone therapy for pyelonephritis caused by ESBL-producing E. coli significantly delays recovery, with mean time to defervescence of 4.6 days versus 2.6 days for non-ESBL cases, and results in longer hospitalization (13.3 vs 7.3 days). 2
Appropriate Dosing
The recommended dose is cefepime 1-2 g IV every 12 hours, with the higher 2 g dose preferred for serious infections like febrile pyelonephritis. 1 The European Association of Urology guidelines specifically note that while lower doses have been studied, higher doses are recommended for pyelonephritis. 1
Efficacy Against ESBL Organisms
Cefepime demonstrates reasonable efficacy against ESBL-producing Enterobacterales when the MIC is ≤2 mg/L (CLSI) or ≤1 mg/L (EUCAST). 3 In a randomized controlled trial of febrile urinary tract infections caused by ESBL-producing E. coli, cefepime showed a clinical and microbiological response rate of only 33.3%, which was significantly inferior to piperacillin-tazobactam (94%) and ertapenem (94%). 4 However, this poor performance may have been related to specific MIC values or ESBL genotypes in that study.
Critical Caveats and Monitoring
You must reassess clinical response within 48-72 hours and be prepared to escalate to a carbapenem if fever persists. 1 The guidelines explicitly state that additional imaging (CT scan) should be considered if the patient remains febrile after 72 hours of treatment. 1
Recent data suggest that even when organisms are cefepime-susceptible, empiric cefepime for ceftriaxone-resistant Enterobacterales is associated with longer time to clinical stability (38.5 hours vs 21.3 hours) compared to meropenem. 5 This delay in clinical response, even with susceptible organisms, underscores the importance of close monitoring.
When to Consider Alternatives
If susceptibility results reveal an ESBL-producer with cefepime MIC >2 mg/L, or if the patient shows clinical deterioration or fails to improve within 48-72 hours, switch immediately to a carbapenem (meropenem 1 g IV every 8 hours or imipenem 500 mg IV every 6 hours). 1 Carbapenems remain the gold standard for ESBL infections and should not be delayed in critically ill patients or those with septic shock. 1
Duration of Therapy
Once the patient responds clinically, complete a total of 7 days of β-lactam therapy for pyelonephritis. 6 This shorter duration has been validated in multiple trials and is now the standard recommendation.
Neurotoxicity Warning
Monitor for neurological adverse events including encephalopathy, confusion, hallucinations, myoclonus, and seizures, particularly if the patient has renal impairment requiring dose adjustment. 7 These neurotoxic effects are a recognized complication of cefepime therapy.